Combined Screening Suggested to Better Detect ALK Rearrangements in Samples from Non-Small-Cell Lung Cancer Patients
By LabMedica International staff writers Posted on 12 Mar 2014 |
Anaplastic lymphoma kinase (ALK) rearrangements occur in 1% to 7% of non-small-cell lung cancers (NSCLCs), but nearly 25% of samples from NSCLC patients with ALK rearrangements were not identified when analyzed by either fluorescent in situ hybridization (FISH) or immunohistochemistry (IHC).
Investigators at the Université de Rennes (France) reported results from a large series of parallel FISH and IHC ALK testing in 3244 consecutive NSCLC cases analyzed at two independent French centers. The results revealed FISH-positive and/or IHC-positive results in 150 of the 3244 cases (4.6%). An imbalanced sex ratio was detected, with women exhibiting a 2.2-fold relative risk for an alteration. Strikingly, only 80 of 150 specimens were classified as ALK positive by both techniques. The specimens with discordant FISH/IHC analyses were FISH-positive/IHC-negative (36), FISH-negative/IHC-positive (19), or FISH-noncontributive/IHC-positive (15). Thus, a single FISH or IHC analysis performed alone would have failed to detect approximately one-fourth of the ALK-positive cases.
The drug crizotinib, an ALK inhibitor, has been demonstrated to provide dramatic clinical benefits in ALK-positive advanced-stage NSCLC. “Data on crizotinib response in patients who have been diagnosed differently by FISH and IHC are still preliminary,” said first author Dr. Florian Cabillic, a researcher at the Université de Rennes. “Thus, until large-scale studies in patients under therapy with crizotinib determine which testing is the most relevant to predict responses to ALK inhibition, our data support the need to routinely perform both analyses because of the difficulty in detecting the chimeric ALK protein in NSCLC and the presence of false-negative cases for each method.”
The study was published in the March 2014 issue of the Journal of Thoracic Oncology.
Related Links:
Université de Rennes
Investigators at the Université de Rennes (France) reported results from a large series of parallel FISH and IHC ALK testing in 3244 consecutive NSCLC cases analyzed at two independent French centers. The results revealed FISH-positive and/or IHC-positive results in 150 of the 3244 cases (4.6%). An imbalanced sex ratio was detected, with women exhibiting a 2.2-fold relative risk for an alteration. Strikingly, only 80 of 150 specimens were classified as ALK positive by both techniques. The specimens with discordant FISH/IHC analyses were FISH-positive/IHC-negative (36), FISH-negative/IHC-positive (19), or FISH-noncontributive/IHC-positive (15). Thus, a single FISH or IHC analysis performed alone would have failed to detect approximately one-fourth of the ALK-positive cases.
The drug crizotinib, an ALK inhibitor, has been demonstrated to provide dramatic clinical benefits in ALK-positive advanced-stage NSCLC. “Data on crizotinib response in patients who have been diagnosed differently by FISH and IHC are still preliminary,” said first author Dr. Florian Cabillic, a researcher at the Université de Rennes. “Thus, until large-scale studies in patients under therapy with crizotinib determine which testing is the most relevant to predict responses to ALK inhibition, our data support the need to routinely perform both analyses because of the difficulty in detecting the chimeric ALK protein in NSCLC and the presence of false-negative cases for each method.”
The study was published in the March 2014 issue of the Journal of Thoracic Oncology.
Related Links:
Université de Rennes
Latest Pathology News
- Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
- AI Advancements Enable Leap into 3D Pathology
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy